Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Tumor Microenvironment Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SPP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SPP1 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. HEK293 Expressed (Native Glycosylation). Available as full-length and thrombin-cleaved variants. |
View SPP1 Products |
| Gene Delivery | SPP1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to study endogenous secretion and receptor interaction. |
View SPP1 Products |
| Benchmark Ab | Anti-SPP1 Recombinant Antibody Recombinant positive control for assay validation and benchmark comparison. |
View SPP1 Products |
| Validator | SPP1 siRNA Set For knockdown verification in functional cell-based assays. |
View SPP1 Products |
| Related Target A | CD44 Key cell-surface receptor for SPP1. Mediates tumor cell migration, survival, and chemotaxis. |
View CD44 Products |
| Related Target B | ITGAV (Integrin alpha V) Forms heterodimers (e.g., alpha-v-beta-3) that bind to the RGD motif of SPP1, driving angiogenesis and macrophage recruitment. |
View ITGAV Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native Glycosylation & Phosphorylation | HEK293 mammalian expression system guarantees complex post-translation modifications crucial for native receptor binding |
| Cleaved vs. Full-Length Specificity | Sequence-verified truncation mutants representing thrombin-cleaved fragments (N-half and C-half) to screen for cleavage-specific blockers |
| Lack of Controls | Sequence-verified Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live SPP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SPP1 therapeutics is intensifying, with major players shifting focus from traditional systemic mAbs to tumor microenvironment (TME)-targeted and macrophage-modulating therapies. As first-generation monoclonal antibodies targeting SPP1 reach clinical evaluation, the next wave of R&D is targeting SPP1-positive tumor-associated macrophages (TAMs) to reverse immune exclusion and overcome anti-PD-1/PD-L1 resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Pfizer, Academic Institutes | NASH, Fibrosis, Solid Tumors | Receptor Blocking Assays (Need HEK293-expressed SPP1 and CD44/Integrin proteins) |
| siRNA / RNAi | Alnylam, Arrowhead | Chronic Liver Diseases, NASH | Knockdown validation (Need sequence-verified SPP1 siRNA and qPCR/Western detection) |
| Bispecific / Combination | Oncology biotechs | Immune-cold Tumors | Dual-targeting affinity validation (Need high-purity SPP1 and co-target antigens like PD-L1) |